AstraZeneca PLC · LSE:AZN
AstraZeneca — Technical Presentation (2000)
22 slides from AstraZeneca's technical presentation, 2000
Slide 1: AstraZeneca Discovery
A AstraZeneca Discovery Professor Jan M Lundberg Senior Vice President, Head of Global Discovery Building leading AZ Discovery b Future healthcare needs and challenges b AZ drug discovery approach b AZ exploiting the science & technology revolution b AZ delivering enhanced productivity & quality A J
Slide 2: Future healthcare needs and challenges
Future healthcare needs and challenges Living longer Obesity epidemic Smoking addiction A The challenges of new treatment paradigms Scientific challenges Cure Disease prevention Stop disease progression Symptomatic treatment Increasing safety and delivery convenience Individualised, coupled to diagn
Slide 3: AstraZeneca Global Discovery
Building leading AZ Discovery b Future healthcare needs and challenges b AZ drug discovery approach b AZ exploiting the science & technology revolution b AZ delivering enhanced productivity & quality A AstraZeneca Global Discovery Mölndal B Södertälje Charnwood Lund Montreal Alderley Boston Reims Wi
Slide 4: Building Discovery in North America
Building Discovery in North America Boston Wilmington Montreal Cancer/Infection CNS Pain Control Enabling Science & Technology B Improved access to science and technology – Local sites – University collaborations & Biotechs A Creating an excellent environment for scientific innovation - ‘nurture the
Slide 5: AZ strong disease focus & drug-hunting expertise
AZ Global Discovery Respiratory CNS Cardiovascular Cancer Inflammation Pain Control Gastrointestinal Infection Safety Assessment Enabling Science & Technology (EST) (Chemistry, Biology, Informatics) A AZ strong disease focus & drug-hunting expertise Disease pathophysiology Novel disease-linked Proof
Slide 6: AZ Research Areas - exploiting breaking science
Medicinal Chemistry High Throughput Pharmacology Screening Bioscience Target Protein Drug metabolism Production - pharmacokinetics - bioanalysis Molecular Toxicology/ Biology Product Safety Assessment Genetics Pharmaceutical & Analytical R&D Commercial Process input R&D Medical input Regulatory Pate
Slide 7: AZ way to external collaborations
Enabling Science & Technology (EST) integration structural EST Chemistry screening chemistry Target Target Compound Compound Concept RAs Identification Validation Identification Optimisation Testing • genetics • genomics • protein for • transgenic • genomics EST Biology HTS disease • transgenics • g
Slide 8: Maximising the global assets of AZ Discovery
Maximising the global assets of AZ Discovery B Shared science areas – Safety Assessment, Inflammation, Nervous system B Shared technology platforms – Enabling Science & Technology B Shared thematic target research – GPCRs, kinases ‘Enhanced efficiency, B Shared best practice speed & innovation’ – Mo
Slide 9: AZ front-loading drug metabolism & pharmacokinetics
AZ front-loading drug metabolism & pharmacokinetics Plasma drug level Rapid metabolism Therapeutic window Ideal for once daily 24 h B Increasing influence of DMPK on early project lead generation B In vivo and in silico prediction of drug absorption Improve likelihood of clinical success A AZ Invest
Slide 10: Clinical proof of concept
Clinical proof of concept AZ Experimental Medicine B Rapid verification of hypothesis in man: early stop-go decisions B Markers of pharmacological activity: gene expression, biochemical, functional imaging B Pharmacogenetics: DNA archive, high 1 throughput genotyping, genetic pre-selection 0.5 Impro
Slide 11: AZ continues finding the unique targets
Building leading AZ Discovery b Future healthcare needs and challenges b AZ drug discovery approach b AZ exploiting the science & technology revolution b AZ delivering enhanced productivity & quality A AZ continues finding the unique targets B Major unmet HCI medical need Parietal Cell B Key functio
Slide 12: AZ exploitation of the genomic revolution
AZ exploitation of the genomic revolution B Great opportunities to understand disease mechanisms and to identify new drug targets B Maximise internal activities with exploitation of genome collaborations – Incyte, Affymetrix, Procardis/Oxagen, SNP consortium etc. – Focus on building Target Validatio
Slide 13: AZ thematic GPCR research
AZ thematic GPCR research B Human genome contains hundreds of novel G-protein coupled receptors (GPCRs) B Ideal drug targets - drugable (>100 drugs on market) B 35 AstraZeneca current Discovery projects on this target class B >6 CDs this year B Viozan™ : inhaled, dual DA2β2 stimulator in COPD A AZ t
Slide 14: Balancing the risk in drug discovery
Balancing the risk in drug discovery Kinase Proportion of drug discovery effort Difficult <25% (Protein - protein) Drugable >75% (GPCR, kinases proteases, Nuclear R) Undesirable <5% GPCR (Cytokine R, GF-R) Do-ability of Target Classes A AZ leading Synthetic and Medicinal Chemistry Lead generation /
Slide 15: AZ sources of chemical leads
AZ sources of chemical leads Best in class Chemical diversity Natural Known products compounds (patents) AZ compound High- collection Throughput (> 1,000,000) Screening (HTS) Natural Directed libraries ligands Increasing Rational design success (structure-led) A Sophisticated cell function analysis
Slide 16: AZ natural product screening and isolation
AZ natural product screening and isolation Unique diverse extract library B Many of top pharmaceuticals have natural product origin B Exceptional chemical diversity - meet target explosion B Unique Australian collection of rainforest plants, marine organisms, fungi, venoms etc. A Rational structure-
Slide 17: AZ exploitation of structural chemistry
AZ exploitation of structural chemistry X-ray crystallography NMR Melagatran in active site of thrombin PPAR ligand binding A Exploiting AZ Cheminformatics B Compound collection Wilmington AstraZeneca Alderley Park analysis and Global HTS enhancement Charnwood Mölndal B High-Throughput Screening enh
Slide 18: AZ 'Integrative Pharmacology'
AZ ‘Integrative Pharmacology’ B Differentiating AZ strength B Allows complete biosystem analysis: target validation, safety, efficacy, DMPK, surrogate markers B Ensure clinical success Patients A GI ‘Integrative Pharmacology’ b Therapeutic concept – Reduce amount of gastric refluxate in esophagus b
Slide 19: CV 'Integrative Pharmacology'
CV ‘Integrative Pharmacology’ b Therapeutic concept Insulin Diet Insulin Liver increased fatty acid levels Adipose – Normalise insulin issue Insulin resistance, glucose levels and dyslipidemia Skeletal muscle b Researchability Lipoproteins – Understand fatty acid fluxes and lipoproteins – PPAR trans
Slide 20: Novel, high quality CD delivery 2000
Building leading AZ Discovery b Future healthcare needs and challenges b AZ drug discovery approach b AZ exploiting the science & technology revolution b AZ delivering enhanced productivity & quality A Novel, high quality CD delivery 2000 (Approved to date*) Research Area Target Class Indication Can
Slide 21: Why is AstraZeneca Discovery special?
Why is AstraZeneca Discovery special? The right balance and drug-hunting competence Disease area focus with technology integration Genomics vs Chemistry vs ‘Integrative Pharmacology’ Internal vs External investment Turning information into knowledge Empowered delivery culture within global framework
Slide 22: Our people make the difference!
Big Pharma power with start-up company innovation Our people make the difference! A Jan Lundberg - Discovery Page 22